Small group, but not small enough that the results can simply be ignored by sufferers, the wider medical community, and regulatory bodies. Months and months of treatment and no side effects and an apparent delay of symptoms at worst. Sometimes, it beggars belief that a life extending treatment cannot be fast tracked and widened out to a community, where currently, there is only one horrible, short term outcome.
Ann: Final Ethics Approval for Open-Label MND Extension Study, page-9
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.020(8.89%) |
Mkt cap ! $96.99M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.5¢ | 22.5¢ | $150.8K | 649.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 50607 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
0.020 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 24.0¢ | 22.5¢ | 231366 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| PAA (ASX) Chart |
